HUTCHMED (China) Limited (AIM:HCM)
174.28
-0.22 (-0.13%)
May 27, 2026, 3:55 PM GMT
HUTCHMED (China) Employees
HUTCHMED (China) had 1,796 employees as of December 31, 2025. The number of employees decreased by 15 or -0.83% compared to the previous year.
Employees
1,796
Change (1Y)
-15
Growth (1Y)
-0.83%
Revenue / Employee
226.92K GBP
Profits / Employee
189.02K GBP
Market Cap
1.52B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,796 | -15 | -0.83% |
| Dec 31, 2024 | 1,811 | -177 | -8.90% |
| Dec 31, 2023 | 1,988 | -37 | -1.83% |
| Dec 31, 2022 | 2,025 | 265 | 15.06% |
| Dec 31, 2021 | 1,760 | 480 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Haleon | 24,535 |
| Hikma Pharmaceuticals | 9,400 |
| Allergy Therapeutics | 584 |
| ECO Animal Health Group | 200 |
| Shield Therapeutics | 63 |
| Venture Life Group | 43 |
| Chill Brands Group | 11 |
| Provexis | 2 |
HUTCHMED (China) News
- 5 days ago - HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 6 days ago - Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma - Nasdaq
- 6 days ago - HCM Receives Approval for New Cancer Treatment in China - GuruFocus
- 6 days ago - Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination - TheFly
- 6 days ago - Hutchmed, Innovent Biologics announce China NMPA approval for NDA - TheFly
- 6 days ago - HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - GlobeNewsWire
- 6 days ago - Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma - PRNewsWire
- 7 days ago - Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites - GlobeNewsWire